Core Viewpoint - The company, Guoshengtang, demonstrates strong resilience in performance growth, with a projected revenue increase in the second quarter of 2025 surpassing that of the first quarter due to rapid store expansion and a stable policy environment [1][2]. Group 1: Performance and Growth - In Q1 2025, Guoshengtang's offline patient visits increased by 12.7% year-on-year, showing a month-on-month acceleration trend [1]. - The company plans to open 15-20 new stores in 2025, including self-built and acquired locations, and aims to enter 2-3 new cities [1]. - Guoshengtang's revenue growth in the second half of 2025 is expected to exceed that of the first half due to base effects [1]. Group 2: Technological Advancements - On June 7, 2025, Guoshengtang launched the first national AI digital twin of a traditional Chinese medicine (TCM) expert, Professor Li Hao, which utilizes deep learning from over 40 years of clinical experience [2]. - The company plans to release 20 AI digital twins of renowned doctors in 2025 to enhance overall diagnostic quality and address the shortage of quality TCM resources [2]. - A partnership with Huawei was established in May 2025 to promote AI technology applications in the TCM field [2]. Group 3: Financial Returns and Shareholder Value - In 2024, Guoshengtang returned a total of 420 million yuan to investors through dividends and buybacks, equivalent to 137% of the company's net profit for that year [3]. - As of June 25, 2025, the company has repurchased approximately 85 million HKD worth of shares, representing 1.1% of the total share capital at the beginning of the year [3]. - The company is expected to continue rewarding shareholders through dividends and buybacks due to strong profitability and cash flow [3].

证券研究报告 | 2025年06月22日 医药生物周报（25 年第 24 周） 优于大市 政策出台加速+AI 应用落地有望带来医疗服务行业新增长 本周医药板块表现强于整体市场，生物医药板块领涨。本周全部 A 股下跌 0.21%（总市值加权平均），沪深 300 下跌 0.25%，中小板指下跌 0.65%， 创业板指上涨 0.22%，生物医药板块整体上涨 1.40%，生物医药板块表 现强于整体市场。分子板块来看，化学制药上涨 3.53%，生物制品上涨 0.33%，医疗服务上涨 2.42%，医疗器械下跌 0.52%，医药商业下跌 0.83%，中药下跌 0.32%。医药板块当前市盈率（TTM）为 34.88x，处 于近 5 年历史估值的 74.55%分位数。 生育津贴政策持续推进完善，催生辅助生殖需求提升。自政府工作报告提 出支持生育意愿以来，多地陆续推出生育利好政策，如呼和浩特市为生 育一孩、二孩、三孩分别提供 1 万、5 万、10 万元补贴。目前，全国超 过 20 个省份已实施生育补贴制度，包括现金、购房补贴和育儿假等。 政策的落地推动了生育意愿提升，同时辅助生殖纳入医保也促进了 IVF 渗透率的增长。近 30 ...

6月7日，中华中医药学会中医与健康保险融合发展研究联合体成立大会暨AI驱动下的中医智慧传承与 创新学术研讨会在上海召开。此次会上，固生堂(02273.HK)发布了首个"国医AI分身"产品以及"AI健康 助理"产品，并对其在AI领域的布局和规划进行了详细介绍。 这之中，国医AI分身产品的重磅出炉，引发市场强烈反响，其被认为是AI技术在传统中医领域深度应 用的重要里程碑，有望重塑中医行业的服务模式与竞争格局。不妨就此来一探究竟。 1、十年饮冰，构建价值成长飞轮 此次，固生堂已上线的首个国医AI分身，即广东省名中医李浩主任国医AI分身，其作用是通过将名医 能力通过AI分身复制出来，结合其本人及工作室团队，能服务更多患者，大幅提升优质医疗供给能 力。 这背后的底层逻辑不难理解，实际上，像DeepSeek这类大模型，其深度思考模式与中医专家的辨证逻 辑有异曲同工之妙。 中医的辨证施治核心在于医生对患者整体状态的精准把握，通过望、闻、问、切四诊合参，结合个人经 验，为患者制定个性化的治疗方案。而像DeepSeek这样的大模型，其多维度数据分析及复杂逻辑推理 能力，能够模拟这一过程。 基于此，固生堂打造名医AI分身，可谓意 ...